Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Usher syndrome in which the cause of the disease is a mutation in the HARS gene.
Features include always present findings: Hyperactive patellar reflex, Hearing loss (hearing impairment), Truncal ataxia, and Photophobia and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Visual impairment, Optic disc pallor, Attenuation of retinal blood vessels |
HARS1 encodes histidyl-tRNA synthetase 1 (509 aa). Catalyzes the ATP-dependent ligation of histidine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (His-AMP). Plays a role in axon guidance Highest expression in Brain Cerebellar Hemisphere (82.0 TPM) and Brain Cerebellum (73.9 TPM).
Usher syndrome type 3B is associated with mutations in the HARS1 gene on chromosome 5.
HARS1 is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for HARS1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 10 always present features.
No clinical trials have been registered for Usher syndrome type 3B.
5 publications have been identified in PubMed for Usher syndrome type 3B. Research spans Case Report / Case Series (40%), Review / Meta-Analysis (20%), and Epidemiology / Natural History (20%).
Siu VM (2026). [PMID: 42157369](https://pubmed.ncbi.nlm.nih.gov/42157369/). *Am J Med Genet A*. [Gene Therapy / Novel Therapeutics]
Samuels TN (2025). [PMID: 39702998](https://pubmed.ncbi.nlm.nih.gov/39702998/). *The FEBS journal*. [Review / Meta-Analysis]
Gélvez N (2025). [PMID: 41060164](https://pubmed.ncbi.nlm.nih.gov/41060164/). *Biomedica : revista del Instituto Nacional de Salud*. [Case Report / Case Series]
Rogic S (2025). [PMID: 40719025](https://pubmed.ncbi.nlm.nih.gov/40719025/). *Disease models & mechanisms*. [Epidemiology / Natural History]
Wilhelm SDP (2024). [PMID: 39352000](https://pubmed.ncbi.nlm.nih.gov/39352000/). *IUBMB life*. [Case Report / Case Series]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:20 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Usher syndrome type 3B
2 |
Truncal ataxia, Delayed gross motor development |
Ears | 1 | Hearing loss (hearing impairment) |
Muscles | 1 | Delayed gross motor development |